Clinical Trials match your criteria
-
Study of MT-5111 in HER2-positive Solid Tumors (MT-5111)
A Phase 1b Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors
-
Confirm RX
Confirm Rx Insertable Cardiac Monitor SMART Registry
-
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis
-
Randomized Phase 3 trial of IO102-IO103 (IDO-PD-L1) dual-antigen immunotherapeutic plus pembrolizumab versus pembrolizumab alone in unresectable or metastatic (advanced) melanoma
An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma.
-
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
-
Registry for Radiation Therapy
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy
-
Retrospective Evaluation of Intensity Modulated Electron Therapy in the Treatment of Patients with Radiation Therapy
Retrospective Evaluation of Intensity Modulated Electron Therapy in the Treatment of Patients with Radiation Therapy
-
Retrospective Radiotherapy Treatment Planning Analysis for Painful Bone Metastases
Retrospective Radiotherapy Treatment Planning Analysis for Painful Bone Metastases
-
Treatment Planning Analysis for Painful Bone Metastases Radiother
Treatment Planning Analysis for Painful Bone Metastases Radiotherapy
-
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
